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Abstract
Background: Smoking cessation services are available in England to provide assistance to those wishing to
quit smoking. Data from one such service were analysed in order to investigate differences in quit rate between
males and females prescribed with different treatments.
Methods: A logistic regression model was fitted to the data using the binary response of self-reported quit
(failed attempt = 0, successful attempt = 1), validated by Carbon Monoxide (CO) monitoring, 4 weeks after commencing
programme. Main effects fitted were: client gender; age; region; the type of advisory sessions; and pharmacotherapy,
Nicotine Replacement Therapy (NRT) or Varenicline. A second model was fitted including all main effects plus two-way
interactions except region. These models were repeated using 12-week self-reported quit as the outcome.
Results: At 4 weeks, all main effects were statistically significant, with males more likely (odds ratio and 95 % CI,
females v males = 0.88 [0.79–0.97]), older smokers more likely (adjusted odds ratios [OR] and 95 % confidence interval [CI]
respectively for groups 20–29, 30–49, 50–69 and 70+ vs 12–19 age group: 1.79 [1.39–2.31], 2.12 [1.68–2.68], 2.30 [1.80–2.
92] and 2.47 [1.81–3.37] and for overall difference between groups, χ2(4) = 53.5, p < 0.001) and clients being treated with
Varenicline more likely to have successfully quit than those on NRT (adjusted OR and 95 % CI for Varenicline vs NRT = 1.41
[1.21–1.64]). Statistically significant interactions were observed between (i) gender and type of counselling, and (ii) age
and type of counselling. Similar results were seen in relation to main effects at 12 weeks except that type of counselling
was non-significant. The only significant interaction at this stage was between gender and pharmacotherapy
(adjusted OR and 95 % CI for females using Varenicline versus all other groups = 1.43 [1.06–1.94]).
Conclusion: Gender and treatment options were identified as predictors of abstinence at both 4 and 12 weeks after
quitting smoking. Furthermore, interactions were observed between gender and (i) type of counselling received (ii)
pharmacotherapy. In particular, the quit rate in women at 12 weeks was significantly improved in conjunction with
Varenicline use. These findings have implications for service delivery.
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Background
Smoking is a major cause of mortality and ill health
worldwide [1]. Despite well-known associations with
cancer of the lungs and other organs [2], and cardiovascu-
lar disease [3], the number of smokers in populations
across the world remains high. According to the World
Health Organization (WHO), 21 % of the global popula-
tion aged 15 years and above smoke tobacco, and men
smoke at five times the rate of women; 36 % vs. 7 %
respectively [4]. Healthcare systems devote significant
effort to promoting smoking cessation given the potential
health benefits to the population, potential reduction of
health service utilisation and saving of health expenditure
due to morbidity attributable to smoking. This is import-
ant in the context of increasing pressures on healthcare
budgets [5]. In the UK, smoking cessation support is
provided to anyone wishing to quit through a number of
specialised evidence-based services, generally known as
“Stop Smoking Services” [6]. These services adhere to
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national guidelines provided by the National Centre for
Smoking Cessation and Training [7], and National Institute
for Health and Care Excellence [8], ensuring provision of
effective and cost effective interventions. A client accessing
these services is assisted by qualified smoking cessation
advisers, who utilise behavioural change techniques in
combination with tailored pharmacotherapy.
Smoking cessation services, or components of them,
may not work equally across the target population. A
number of studies have identified gender differences in
relation to smoking quit rates. However, no universal
consensus emerges in relation to the nature of this differ-
ence. Some studies report a statistically higher success rate
for males [9–12], some suggest women are more likely to
succeed in quitting [13], and in others the picture is
inconclusive [14–16]. This lack of consistency may be
related to differences between the study populations and
smoking cessation interventions investigated. Different
patterns are seen between male and female smokers in
terms of behavioural patterns underlying smoking habit
[9] and personal characteristics [17] as well as use and
experience of smoking cessation services [18].
In the UK, three pharmaceutical interventions are
currently offered as part of the smoking cessation service
programme: Nicotine Replacement Therapy (NRT),
Varenicline (Champix) and Bupropion (Zyban). All of
these have been shown to enhance smoking quit rates
relative to placebo/no treatment, with the best figures
generally being seen in relation to Varenicline use [19–21]
and no consistent difference emerging between Bupropion
and NRT when considering results from different studies
[22].
A few studies have looked into the relative benefits of
pharmaceutical interventions in men and women.
Amongst these, there is some evidence for the presence
of interactions between gender and pharmaceutical
agents that are available in the UK [10, 23–25] and also
Topiramate in the United States [26].
The use and effect of smoking cessation services
among different demographic subgroups of the popula-
tion is not currently well understood. However, the char-
acteristics of different subgroups is potentially important
as a basis for adapting treatment programmes to meet
the needs of different groups and optimising smoking
quit rates across the population as a whole.
This study utilised a large dataset recorded by Quit-51
[27], one of a number of smoking cessation service
providers in England. The aim was to assess (i) whether
there is a difference in quit rate between males and
females, (ii) whether there is a difference between males
and females from different pharmaceutical interventions
in the endeavour to quit smoking, and (iii) whether other
factors influence outcomes for men and women and the
benefit obtained from pharmaceutical interventions.
Methods
Data were provided by Quit-51 based on clients attempting
to quit smoking in four regions in England where the
service operates (East Sussex, Sandwell, Walsall and
Worcestershire). Quit-51 record a number of metrics on
clients using the service, including individual-level informa-
tion such as age and gender (male/female) of the client and
details of the programme followed (treatment prescribed,
the venue chosen for advisory sessions, number of sessions
attended etc.). For analytical purposes, information was
extracted on client gender, age, pharmacotherapy used
(where information was available), the type of counselling
taken up (one-to-one counselling, group sessions etc.) and
various measures of quit success/failure.
The original dataset comprised a total of 7581 records
on 6614 clients using the Quit-51 service across the four
regions mentioned above between 15 March 2013 and
21 September 2015 (with reference to quit date). There
was a small degree of replication, i.e. clients who used
the system more than once. Records were removed
where (i) the client was recorded as having been
prescribed Bupropion for pharmacotherapy, n = 38; (ii)
where more than one pharmaceutical treatment was re-
corded, n = 268; (iii) where the recorded age was less
than 12 or greater than 93 or not recorded, n = 26.
Restrictions (i) and (ii) were applied because the sample
sizes were too low to make a meaningful comparison
with the other treatments. Restriction (iii) was applied as
ages recorded outside the range 12 – 93 years were
considered likely to be erroneous. Applying the above
criteria reduced the dataset from 7581 to 6959 records.
In terms of replication, 5399 individuals appeared in the
dataset once and 673 appeared more than once.
An initial model was fitted in which the response
variable was a self-reported quit 4 weeks after the initial
quit date supported by a blood Carbon Monoxide (CO)
reading below 10 parts per million, in accordance with
the Russell standard [28]. Quit status was recorded as
“Y” (abstinent at stated time), “N” (smoking again at
stated time), “L” (lost to follow-up) and in some cases
the field was empty. Both “L” and missing cases were
treated as unsuccessful quit attempts. Because of the
binary nature of the outcome, analyses were carried out
using logistic regression [29]. Although a degree of repli-
cation was present in terms of some clients appearing in
the dataset more than once, data were treated as inde-
pendent in analysis as this was a relatively rare
phenomenon and considered unlikely to significantly
bias statistical inference.
Random variation in the response was modelled with a
Bernoulli distribution and dispersion fixed at unity.
Explanatory variables fitted were: (i) gender, (ii) age, (iii)
region, (iv) type of counselling, and (v) pharmacother-
apy. A second model was fitted including, in addition to
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the above, all two-way interactions except those involv-
ing region. A backwards stepwise regression approach
was applied removing interactions where statistical
significance, as measured by the corresponding p-value,
was above an a priori threshold of 5 % until only signifi-
cant two-way interactions remained in the model.
Adjusted odds ratios [30] and corresponding 95 %
confidence intervals (CI) for key main effects and interac-
tions are presented. Statistical inference was based on
Chi-squared tests when considering the overall effect of a
variable. With respect to the interaction model, only
statistically significant two-way interactions are presented.
Similarly, the main effect and interaction models were
fitted to the data using the 12-week self-reported quit as
response variable. All analyses were carried out in
Genstat [31].
Results
Frequencies and percentages are presented for each
category of each variable for the dataset of 6959 records
in Table 1. Similarly, the frequencies and percentages of
male and female records across levels of all other
variables in the models are given in Table 2. More than
half the records (54.2 %) came from East Sussex and
about a third (33.5 %) from Sandwell. In terms of
pharmacotherapy, NRT was much more frequently used
than Varenicline (87.4 % vs. 12.6 % records for NRT and
Varenicline respectively) and there were somewhat more
female users of the system (56.1 % vs. 43.9 % female and
male records respectively). Heterogeneity in frequency of
service use between males and females was present
across different age groups with a high frequency of fe-
males users in the 20–29 year age group (63.8 % records
in this age group from female clients) and a correspond-
ingly low percentage amongst the over 70s (49.3 % re-
cords). The percentage of females in the Varenicline
group was somewhat lower than in the sample as a
whole (53.0 % of the subgroup prescribed Varenicline
were female vs. an overall average of 56.1 %). Other ob-
served differences are likely to have been influenced by
low sample size and thus greater error around the mean.
Four-week quit models
All variables fitted as part of the main effects model were
statistically significant (Table 3). Males were found to have
a better chance of quitting than females after 4 weeks.
Elsewhere, the data show a progressive increase in quit
rate with age, although this did not appear to happen in a
Table 1 Frequencies (number of observations and %) across
levels of key variables, N = 6959
Variable Category N (%)
Regiona East Sussex (1/1/14 to 21/9/15) 3773 (54.2 %)
Sandwell (15/3/13 to 18/9/15) 2331 (33.5 %)
Walsall (15/4/14 to 30/8/15) 140 (2.01 %)
Worcestershire (14/4/13 to 30/8/15) 715 (10.3 %)
Sex Male 3055 (43.9 %)
Female 3904 (56.1 %)
Age 12–19 426 (6.12 %)
20–29 1041 (15.0 %)
30–49 2963 (42.6 %)
50–69 2158 (31.0 %)
70+ 371 (5.33 %)
Counselling One-to-one 5666 (81.5 %)
Drop-in 350 (5.03 %)
GP 326 (4.69 %)
Pharmacy 207 (2.98 %)
Nurse 165 (2.37 %)
Telephone 185 (2.66 %)
Other 57 (0.82 %)
Treatment NRT 6085 (87.4 %)
Varenicline 874 (12.6 %)
aDates for which data were available for different regions are included
in brackets
Table 2 Breakdown (frequency and %) of female records across
levels of key variables
Variable N (%) % Females
(mean = 56.1 %)
Region
East Sussex 3773 (54.2 %) 56.8 %
Sandwell 2331 (33.5 %) 55.7 %
Walsall 140 (2.01 %) 42.1 %
Worcestershire 715 (10.3 %) 56.6 %
Age
12–19 426 (6.12 %) 53.8 %
20–29 1041 (15.0 %) 63.8 %
30–49 2963 (42.6 %) 55.4 %
50–69 2158 (31.0 %) 55.0 %
70+ 371 (5.3 %) 49.3 %
Counselling
One-to-one 5666 (81.5 %) 56.9 %
Drop-in 350 (5.03 %) 43.7 %
GP 326 (4.69 %) 53.7 %
Pharmacy 207 (2.98 %) 54.1 %
Nurse 165 (2.37 %) 52.7 %
Telephone 185 (2.66 %) 58.4 %
Other 57 (0.82 %) 71.9 %
Treatment
NRT 6085 (87.4 %) 56.5 %
Varenicline 874 (12.6 %) 53.0 %
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linear fashion. In particular, we see a disproportionate
jump in the quit rate going from the 12 to 19 year age
group (34.7 %) to the 20–29 year group (53.1 %) and this is
reflected in the adjusted odds ratio (1.79, 95 % CI = 1.39 to
2.31). Significant variation was present between different
types of counselling with respect to successful 4-week quits.
One-to-one counselling was associated with a high quit rate
(significantly higher than both Pharmacy support and
Nurse support categories). Finally, we see a higher rate of
cessation among smokers using Varenicline as compared to
NRT (63.6 % v 54.9 % respectively, adjusted odds
ratio = 1.41, 95 % CI = 1.21 to 1.64).
In terms of interactions, the 4-week quit model
retained the following two associations: (i) gender and
counselling, and (ii) age and counselling (Table 4). With
respect to sex and counselling, the odds ratios for the in-
teractions between women and Pharmacy Support,
Nurse Support, and Other Support were relatively large,
although the number of clients in the Other support
group was low making reliable estimation difficult. In
terms of age and counselling, the odds ratios for all age
groups above the baseline of 12–19 years in conjunction
with GP Support were all greater than unity.
Twelve-week quit models
Results from the main effects model in relation to 12-
week self-reported quit (Table 5) generally corroborated
those above although the overall quit rate was lower
(27.3 % compared to 56.0 % for 4-week quit). The differ-
ence between Varenicline and NRT was more pro-
nounced after 12 weeks (adjusted odds ratio for
Varenicline v NRT = 2.87, 95 % CI = 2.46 to 3.35 at
12 weeks as compared to 1.41 after 4 weeks). The mag-
nitude of the difference between males and females was
also slightly higher. Age differences followed the same
general pattern with the difference between the older
age groups in relation to the 12–19 year olds being
greater when analysed at 12 weeks.
The only significant interaction was that between gender
and pharmacotherapy (χ2 = 5.3, d.f. = 1, p = 0.02). This
was reflected in an adjusted odds ratio of 1.43 (95 % CI =
1.06 to 1.94) with respect to females using Varenicline and
the effect is clearly demonstrated by the raw data (Fig. 1).
Discussion
The results of this analysis afford an insight into the ef-
fects of smoking cessation services and its components
among men and women in a real-world setting. Much of
the existing evidence for pharmaceutical interventions in
smoking cessation comes from randomised controlled
trials (RCT), demonstrating efficacy in ideal circumstances
which may be significantly different to those in day to day
practice. Real world studies complement RCTs and add to
the evidence base for service delivery mechanisms.
Despite the presence of missing data in relation to
some key fields, the available dataset was nonetheless
large (N = 6959). The possibility of misrecording across
Table 3 GLM model for 4-week validated quit; adjusted odds
ratios with
95 % confidence intervals (CI) and significance results
Variable Level Quit rate –
n/N (%)
Odds ratio
(95 % CI)
Wald
(d.f.)
p-value
Sex 6.7 (1) 0.01
Male 1763/3055
(57.7 %)
1
Female 2133/3904
(54.6 %)
0.88
(0.79–0.97)
0.03
Region 192.9 (3) <0.001
East Sussex 2431/3773
(64.4 %)
1
Sandwell 1069/2331
(45.9 %)
0.49
(0.44–0.55)
<0.001
Walsall 57/140
(40.7 %)
0.38
(0.27–0.54)
<0.001
Worcestershire 339/715
(47.4 %)
0.48
(0.40–0.57)
<0.001
Age 53.5 (4) <0.001
12–19 148/426
(34.7 %)
1
20–29 553/1041
(53.1 %)
1.79
(1.39–2.31)
<0.001
30–49 1690/2963
(57.0 %)
2.12
(1.68–2.68)
<0.001
50–69 1275/2158
(59.1 %)
2.30
(1.80–2.92)
<0.001
70+ 230/371
(62.0 %)
2.47
(1.81–3.37)
<0.001
Counselling 71.7 (6) <0.001
One-to-one 3315/5666
(58.5 %)
1
Drop-in 148/350
(42.3 %)
1.14
(0.88–1.47)
0.4
GP 155/326
(47.5 %)
0.89
(0.70–1.14)
0.2
Pharmacy 82/207
(39.6 %)
0.55
(0.41–0.73)
<0.001
Nurse 64/165
(38.8 %)
0.31
(0.22–0.42)
<0.001
Telephone 108/185
(58.4 %)
1.01
(0.75–1.37)
0.6
Other 24/57
(42.1 %)
0.55
(0.32–0.94)
0.02
Treatment 19.0 (1) <0.001
NRT 3340/6085
(54.9 %)
1
Varenicline 556/874
(63.6 %)
1.41 <0.001
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Table 4 Adjusted odds ratios and 95 % confidence intervals for combinations of significant interactions from model where response is
4-week validated quit (statistically significant ratios presented in bold)
One-to-one Drop-in GP Pharmacy Nurse Telephone Other
Interaction 1: Gender• Counselling (χ2 = 15.1, d.f. = 6, p = 0.02)
Sex
Male 1 1 1 1 1 1 1
Female 1 1.23 (0.78–1.94) 0.82 (0.51–1.29) 2.04 (1.11–3.75) 1.84 (0.96–3.55) 1.02 (0.53–1.96) 5.10 (1.27–20.55)
Interaction 2: Age Group• Counselling (χ2 = 42.5, d.f. = 24, p = 0.011)
Age
12-19 1 1 1 1 1 1 1
20–29 1 1.24 (0.58–2.64) 78.4 (0.1–71986) 0.1 (0.02–0.38) 0.4 (0.02–8.31) 6.7 (0.64–70.74) 2.1 (0.23–19.23)
30–49 1 0.77 (0.43–1.39) 109.6 (0.12–98732) 0.11 (0.03–0.44) 0.29 (0.02–4.93) 2.73 (0.28–26.74) 0.55 (0.09–3.17)
50–69 1 0.90 (0.41–1.97) 76.2 (0.68–68671) 0.1 (0.02–0.30) 0.29 (0.02–5.02) 1.78 (0.18–17.63) 0.14 (0.02–1.33)
70+ 1 48.4 (0.04–54871) 139.1 (0.14–136710) 0.11 (0.02–0.67) 0.34 (0.01–8.35) 0.18 (0.01–3.87) 0.83 (0.03–23.18)
Table 5 GLM model for 12-week self-reported quit; adjusted odds ratios with 95 % confidence intervals (CI) and significance results
Variable Level Quit rate – n/N (%) Odds ratio (95 % CI) Wald (d.f.) p-value
Sex 8.9 (1) 0.003
Male 905/3055 (29.6 %) 1
Female 996/3904 (25.5 %) 0.84 (0.76–0.94) 0.003
Region 334.3 (3) <0.001
East Sussex 702/3773 (18.6 %) 1
Sandwell 913/2331 (39.2 %) 3.28 (2.89–3.73) <0.001
Walsall 37/140 (26.4 %) 1.50 (1.01–2.22) 0.04
Worcestershire 249/715 (34.8 %) 2.29 (1.89–2.77) <0.001
Age 82.7 (4) <0.001
12–19 89/426 (20.9 %) 1
20–29 211/2041 (20.3 %) 1.47 (1.08–2.01) 0.015
30–49 829/2963 (28.0 %) 2.23 (1.68–2.95) <0.001
50–69 661/2158 (30.6 %) 2.72 (2.04–3.63) <0.001
70+ 111/371 (29.9 %) 3.18 (2.22–4.56) <0.001
Counselling 11.8 (6) 0.07
One-to-one 1479/5666 (26.1 %) 1
Drop-in 130/350 (37.1 %) 1.43 (1.09–1.87) 0.01
GP 125/326 (38.3 %) 1.05 (0.81–1.36) 0.7
Pharmacy 68/207 (32.9 %) 1.17 (0.86–1.59) 0.3
Nurse 35/165 (21.2 %) 0.80 (0.54–1.19) 0.3
Telephone 53/185 (28.6 %) 1.13 (0.81–1.59) 0.5
Other 11/57 (19.3 %) 0.57 (0.28–1.17) 0.1
Treatment 175.8 (1) <0.001
NRT 1513/6085 (24.9 %) 1
Varenicline 388/874 (44.4 %) 2.87 (2.46–3.35) <0.001
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different variables cannot be discounted. However, the
size of the dataset is likely to provide a safeguard against
bias arising from any resulting extra noise assuming
such misrecording was rare and not systematic.
Differences emerge between men and women with re-
spect to patterns in the use of smoking cessation services.
Overall, there are more instances of women registered
with the system than men (56.1 % v 43.9 % respectively).
This may in part be a result of greater general engagement
with health services by women as reported elsewhere [32].
In terms of age, women are especially well represented
in the 20–29 year age group. It is possible to speculate
that this may be related to a desire to quit smoking among
women of child bearing age, who may be considering hav-
ing a family. Amongst the over 70s, the number of males
and females is almost the same. This may be a result of
disproportionate prevalence of long-term complications of
smoking, such as Chronic Obstructive Pulmonary Disease
(COPD), between men and women in this age group given
historically higher smoking rates in men.
All main effects were significant predictors of 4-week
CO-validated quit success. The finding that males are
more likely to quit has been observed elsewhere. In part,
this may be explicable in terms of a perceived connec-
tion between smoking and weight loss potentially mak-
ing more women reluctant to quit [33, 34]. The size of
the difference reported here, whilst small in statistical
terms, nonetheless translates to a high number of
additional quitters when considered on a national scale
assuming the generalisability of the result.
We see a clear increase in quit rate with age at both 4
and 12 weeks. Improved quit rates with increasing age
have been observed elsewhere [35] although the current
work highlights particularly poor success rates amongst
the teenage cohort, possibly connected to lower health
concerns within this age group. It is understood that
quitting at an early age, e.g. before 35 [36], can almost
completely negate the reduction in life expectancy
attributable to cigarette smoking, thus it is important to
achieve as high rates in this subgroup as possible. Despite
the low rate of cessation observed here amongst teenagers,
studies have nonetheless shown smokers in this age group
to be responsive to cessation programmes [37]. More re-
search is needed to better understand factors likely to en-
hance quit rates amongst early age smokers that can be
incorporated into quit programmes.
The results here support the finding observed elsewhere
that Varenicline is a more effective aid to smoking cessa-
tion than NRT [38]. In accordance with earlier findings,
this effect was more pronounced after 12 weeks, which
suggests longevity in the action of this treatment [39]. The
reason for this may be related to cognitive deficits during
nicotine deprivation [40]. The decision to make Vareni-
cline more widely available for the purposes of smoking
cessation is likely to depend on whether the treatment is
perceived as cost effective and ‘good value for money’,
given wider pressures on health service budgets. Different
modelling studies indicate Varenicline is cost-effective
relative to other treatments [41, 42]. Contraindications
and side-effect profiles also need to be considered in mak-
ing decisions on prescription at an individual level [43].
The outcomes considered here were on a relatively short
timescale (4 and 12 weeks) and the importance of these
results depends on whether these trends persist over a
longer period (e.g. 12 months plus). Successful smoking
cessation at 12 weeks has been shown to be a good indica-
tor of long-term or permanent cessation [44, 45]. In order
to achieve permanent abstinence from smoking many
clients may require long term treatment with pharmaco-
therapy which implies additional cost [44].
Significant differences between the various types of
counselling are somewhat difficult to interpret in light of
the fact that the majority of clients take up one-to-one
advice in this cohort. One-to-one advice is associated with
a higher than average quit rate with respect to 4-week
CO-validated quit (58.5 % v overall average of 56.0 %) but
Fig. 1 Self-reported quit Rate (%) at 12 weeks for males and females prescribed (i) Nicotine Replacement Therapy (ii) Varenicline
Walker et al. BMC Public Health  (2016) 16:1038 Page 6 of 8
a lower than average rate in relation to 12-week self-
reported quitting (26.1 % v overall average of 27.3 %). It is
difficult to identify consistent patterns in both 4-week
CO-validated and 12-week self-reported quit rates and
this is an area which requires further investigation.
The introduction of smoking cessation programmes
with tailored pharmacotherapy remains a relatively re-
cent innovation and it is the case that many smokers will
try to quit unassisted, not least in parts of the world
where such programmes are in their infancy. It would
therefore be of interest to compare cohorts of quitters
both inside and outside of the service. By the nature of
the current data, it was not possible to investigate this
question (by definition, clients in the dataset were
registered with a cessation service). There is ample evi-
dence of the efficacy of individual aspects of the service,
e.g. pharmacotherapy against placebo [19] and counsel-
ling sessions [37], but it would be valuable to see how
these effects operate together in a real-world setting.
The significant interaction between client gender and
pharmacotherapy after 12 weeks indicates that women in
particular benefit from Varenicline use, notwithstanding
lower overall quit rates in relation to men. This accords
with results from meta-analysis of clinical trials [46] and
suggests that efficacy in these trials is mirrored in real life.
The prescription of Varenicline for female quitters is
complicated by concerns regarding its suitability in preg-
nancy [47–49]. Whilst NRT was much more frequently
prescribed by smoking cessation services than Varenicline
in this sample (87.4 % v 12.6 % respectively), men are
more likely to receive Varenicline than women. Again, this
may in part be due to concerns over side-effects from using
Varenicline during pregnancy.
Conclusions
These results from analysis of data on patients using a
smoking cessation service provide an insight into the
effects of interventions in a real world setting. Under the
current prescription, we see that males using the service
are more likely to succeed in quitting. Individual per-
formance is also influenced by age and type of counsel-
ling provided. Varenicline support was found to enhance
the chance of a successful quit in relation to NRT and
this benefit was found to be particularly pronounced for
females when quit success was measured at 4 weeks.
Given that women tend to receive Varenicline as an aid
to smoking cessation less than men, this is an imbalance
which could be redressed in future.
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